Results from the LIBERTY-PN PRIME and PRIME2 phase III trials—published by Yosipovitch et al in Nature Medicine—showed a significant reduction in Worst Itch Numeric Rating Scale (WI-NRS) score in patients with prurigo nodularis treated with the monoclonal antibody dupilumab vs placebo. In addition, patients receiving dupilumab reported improvements in their health-related quality of life; a reduction in the number of their nodules; less use of rescue medication; and improvements in skin pain, anxiety, and depression. Overall, dupilumab was well tolerated and had an overall safety profile consistent with its known profile. The study authors concluded, “These positive studies support the involvement of type 2 cytokines in driving prurigo nodularis disease pathogenesis and the targeting of the interleukin (IL)-4/IL-13 axis as a novel therapeutic paradigm for patients with prurigo nodularis.”